Introduction:
Leading pharma company has announced that its investigational product VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the US FDA for the treatment of bloodstream infections caused by polymyxin B-susceptible strains.
Also Read: Q4 Results: Renewable energy stock jumps 7% after reporting 82% YoY increase in net profits
Share price movement of Venus Remedies:
On April 17, 2025, Venus Remedies Ltd opened at ₹316.00, up 1.42% from its previous close of ₹311.60. The stock reached a high of ₹354.00 (13.62%) and a low of ₹311.90. By 11:37 AM, it traded at ₹339.10, an 8.83% increase, with a market cap of ₹453.27 crore.
Venus Remedies’ VRP-034 Receives USFDA QIDP Designation:
Venus Remedies Limited announced that its investigational product VRP-034 has been granted Qualified Infectious Disease Product (QIDP) designation by the US FDA for treating bloodstream infections.
VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, designed to reduce nephrotoxicity compared to conventional polymyxin B, with up to 70% reduction in nephrotoxic effects in clinical findings.
The QIDP designation under the GAIN Act provides VRP-034 with priority review, eligibility for fast-track designation, and up to five years of market exclusivity upon approval in the United States.
Recent news on Venus Remedies:
As of January 21, 2025, Venus Remedies Ltd announced the renewal of its European Good Manufacturing Practices (EU-GMP) certification by Infarmed, ensuring continued compliance for its Cephalosporin, Carbapenem, and Oncology formulations.
Ace investor holding in Venus Remedies:
K.B. Shekar
K.B. Shekar holds 262,780 shares, representing a 1.97% stake in Venus Remedies Ltd, valued at ₹8.9 crore, showcasing a significant investment in the pharmaceutical company.
Stock performance of Venus Remedies for Period of 1 week, 6 months, and 1 year:
Venus Remedies Ltd delivered a 4.78% return over the past week, but declined by 9.26% in the past six months. The stock decreased by 4.51% over the past year.
Also Read: Textile stock jumps after announcing 1.5:1 bonus issue
Shareholding pattern of Venus Remedies:
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 |
| Promoter | 41.80% | 41.80% | 41.80% |
| FII | 1.30% | 1.10% | 1.20% |
| DII | 0% | 0% | 0.20% |
| Public | 56.90% | 57.10% | 56.90% |
About Venus Remedies:
Venus Remedies Ltd (NSE: VENUSREM), established in 1989, is a research-based pharmaceutical company specializing in injectable manufacturing. It offers a wide range of products across various therapeutic areas, including anti-infective, oncology, and neurology.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
